Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
In2Care Holding B V currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, indicating a concentrated prosecution focus for the portfolio at this stage. The entirety of the pending workload is handled within 1 distinct art unit, which centralizes the technical review process for the company's current applications.
BARBER, KIMBERLY serves as the busiest examiner for the company, responsible for 1 pending office action. This alignment between the total pending actions and the busiest examiner's load suggests a singular point of contact for the firm's current USPTO interactions. Practitioners should note that the 1 pending office action represents the total active engagement across the portfolio, meaning any strategic decisions are currently tied to this specific case.
With only 1 distinct examiner involved, the prosecution strategy is currently dependent on a single individual's interpretation of the Biotechnology & Pharmaceuticals landscape. The presence of 1 distinct art unit further confirms that the company's current legal efforts are focused on a narrow technical niche. This concentration allows for a very specific prosecution approach but limits the diversity of examiner perspectives available to the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARBER, KIMBERLY | 1 | 71.8% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708520 | INSECTICIDE COMPOSITION | BARBER, KIMBERLY | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708520 | INSECTICIDE COMPOSITION | BARBER, KIMBERLY | 1615 | §103 | Non-Final OA | 8d overdue | Pending | May 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIn2Care Holding B V has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kimberly Barber has the most, with 1 of In2Care Holding B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.